Sign in
Taking peoplePhase 1/2

Double-blind placebo-controlled clinical trial (Phase 1b/2a) to evaluate safety and efficacy of IM-250 administration in patients with recurrent genital herpes.

Key facts

Who runs it
Innovative Molecules GmbH
Where
Bulgaria and Estonia2 sites in 2 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 1/2
People taking part
232 people, planned
Started
16 Jan 2025
Expected to end
30 Sept 2027
Type of study
Interventional
Record updated
9 October 2026

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (27)Hide the full registry criteria

Who can take part

  • Age 18-65 years inclusive at the time of consent
  • Men or women who agree to comply with any applicable contraceptive requirements of the protocol
  • Prior history of genital HSV-2, acquired at least 12 months prior to screening according to patient’s report. The laboratory confirmation of HSV-2 infection by positive PCR, or cell culture test, or antibody test. There is no timing requirement for the laboratory confirmation, i.e. it can be performed also at screening
  • For patients currently on suppressive therapy, medical history of 3-9 recurrences within the 12 months prior to initiation of suppressive therapy as reported by the patient during screening interview. Suppressive therapy must be discontinued upon screening and at least 14 days prior to the study medication administration
  • For patients not on suppressive therapy, medical history of 3-9 episodes (with genital lesion) within the last 12 months before screening as reported by the patient during screening interview
  • If applicable, willingness to discontinue systemic or topical antiviral treatment at screening at least 14 days prior study medication administration
  • An understanding, ability, and willingness to fully comply with study interventions and restrictions
  • Ability to provide written, personally signed and dated informed consent to participate in the study, in accordance with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable regulations, before completing any study-related interventions

Who cannot take part

  • Use of another study medication within 30 days prior to receiving the first dose of study medication or enrolment in another drug or vaccine clinical trial
  • History of vaccination within 14 days prior to dosing
  • Prior participation in this trial (randomization)
  • Phase 1b part: A positive result in testing for illegal drugs at screening
  • Medical history or current physical illnesses/medical conditions that constitute an unacceptable risk for study participation in the judgment of the investigator (e.g., clinically significant autoimmune disorder, cancer, active infection, uncontrolled medical conditions or organ system dysfunction that, in the investigator's opinion, could compromise the patient's safety or put the study outcomes at risk, such as uncontrolled hypertension, uncontrolled diabetes mellitus, uncontrolled coronary heart disease, uncontrolled psychiatric condition); Prior to randomization: 20. Any relevant intercurrent illness since screening
  • History of severe allergic or anaphylactic reactions to medications or vaccines
  • Known allergy / hypersensitivity to additives used in the study drug
  • A positive antibody screen for human immunodeficiency virus (HIV), or hepatitis C virus (HCV), or a positive hepatitis B virus surface antigen (HBsAg) test
  • Receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • History of any form of ocular HSV infection or HSV- related erythema multiforme
  • History of drug or alcohol abuse that, in the opinion of the Investigator, would interfere with the patient's ability to comply with the requirements of the study
  • Clinically relevant abnormality in the ECG, defined as one or more of the following or other finding based on a medical evaluation of the recording: a) Prolonged QTcF > 450 ms in males and > 470 ms in females; b) Family history of long QT syndrome; c) PR (PQ) interval shortening < 120 ms (PR > 110 ms but < 120 ms is acceptable if there is no evidence of ventricular pre-excitation); d) PR (PQ) interval prolongation (> 240 ms) intermittent second (Wenckebach block while asleep is not exclusive) or third-degree AV block, or AV dissociation; e) e) Persistent or intermittent complete BBB, IBBB, or IVCD with QRS > 110 ms. Patients with QRS > 110 ms but < 115 ms are acceptable if there is no evidence of e.g., ventricular hypertrophy or pre-excitation
  • Any abnormal laboratory value (hematology, biochemistry, serology, urine analysis) of Grade 2 or higher, which is considered as clinically significant by Investigator at screening
  • Value for ALT and/or AST: ≥ 3 times the upper limit of normal at screening
  • Value for total bilirubin > upper limit of normal (ULN) x 1.2 at screening, where in case of suspected Gilbert´s disease: total bilirubin ≤ ULN x 3 is acceptable
  • Value of creatinine clearance: < 60 ml/min (Cockcroft-Gault equation) at screening
  • Genital herpes episode presence on Day 1 (applies only at randomization)
  • Clinically relevant abnormality in vital signs, defined as one or more of the following or other relevant medical evaluation of the measurements: a) Systolic BP < 90 mmHg or > 150 mmHg; b) Diastolic BP < 50 mmHg or > 100 mmHg; c) Body temperature of > 37.7°C (on admission day). Note: Vital signs are measured after 5 minutes rest. Abnormal values may be repeated once at the discretion of Investigator
  • Pregnancy or lactation

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Genital herpes infection

This trial is currently available in Bulgaria and Estonia.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

To obtain clinical proof of concept for IM-250 in suppressive therapy of genital herpes by investigating different dosing regimens.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Criteria questions
Built from 2024-516368-27-00, who can take part
Record updated
9 October 2026